항생제 Fluoroquinolones의 약동학 및 약력학에 관한 최신 정보
Current Updates in Pharmacokinetics and Pharmacodynamics of Fluoroquinolones
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The ultimate goal of antimicrobial treatment is to decrease the morbidity and mortality related to infection. Maximizing these outcomes requires an understanding of the complex interactions between the drug administered, the host, and the infecting pathogen. Pharmacokinetics, which deals with the disposition of a drug in the body, focuses on such parameters as absorption, distribution, and elimination. Pharmacodynamics more specifically focuses on the interaction between the drug concentration at the site of action over time and the resulting antimicrobial effect. Use of quinolones has increased in vitro activity against several important pathogenic organisms as well as augmented pharmacokinetic parameters. These properties result in enhanced pharmacodynamic characteristics and should improve therapeutic outcomes against selected pathogens. In this article the pharmacokinetics and pharmacodynamic potential of these quinolones, particularly fluoroquinolones, is reviewed.
Abstract
The ultimate goal of antimicrobial treatment is to decrease the morbidity and mortality related to infection. Maximizing these outcomes requires an understanding of the complex interactions between the drug administered, the host, and the infecting pathogen. Pharmacokinetics, which deals with the disposition of a drug in the body, focuses on such parameters as absorption, distribution, and elimination. Pharmacodynamics more specifically focuses on the interaction between the drug concentration at the site of action over time and the resulting antimicrobial effect. Use of quinolones has increased in vitro activity against several important pathogenic organisms as well as augmented pharmacokinetic parameters. These properties result in enhanced pharmacodynamic characteristics and should improve therapeutic outcomes against selected pathogens. In this article the pharmacokinetics and pharmacodynamic potential of these quinolones, particularly fluoroquinolones, is reviewed.
참고문헌 (31)
- Craig WA, "Pharmacokinetic", pharmacodynamic parameters: rationale for antibacterial dosing of mice and men, 1998, pp.26, 1~10
- Mueller M, "Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC", Antimicrob Agents Chemother, 48, pp.369~377 (2004)
- Andriole VT, "The quinolones: past, present, and future", Clin Infect Dis, 41(Suppl 2), pp.S113~S119 (2005)
- Ball P, "Adverse drug reactions: implications for the development of fluoroquinolones", J Antimicrob Chemother, 51(Suppl 1), pp.21~27 (2003)
- Jacoby GA, "Mechanisms of resistance to quinolones", Clin Infect Dis, 41(Suppl 2), pp.S120~S126 (2005)
- O'Donnell JA, "The newer fluoroquinolones", Infect Dis Clin North Am, 18, pp.691~716 (2004)
- Mehlhorn AJ, "Safety concerns with fluoroquinolones", Ann Pharmacother, 41, pp.1859~1866 (2007)
- Montay G, "Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800mg", J Clin Pharmacol, 34, pp.1071~1076 (1994)
- Davis R, "Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy", Drugs, 47, pp.677~700 (1994)
- Nakashima M, "Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers", Antimicrob Agents Chemother, 39, pp.170~174 (1995)
- Cohen KA, "Coadministration of oral levofloxacin with agents that impair absorption: impact on antibiotic resistance", Infect Control Hosp Epidemiol, 29, pp.975~977 (2008)
- Barton TD, "High rate of coadministration of di- or tri-valent cationcontaining compounds with oral fluoroquinolones: risk factors and potential implications", Infect Control Hosp Epidemiol, 26, pp.93~99 (2005)
- Teng R, "Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers", J Antimicrob Chemother, 36, pp.385~394 (1995)
- Child J, "Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin", Antimicrob Agents Chemother, 39, pp.513~515 (1995)
- Johnson JH, "Pharmacokinetics and inflammatory fluid penetration of sparfloxacin", Antimicrob Agents Chemother, 36, pp.2444~2446 (1992)
- Child J, "Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid", Antimicrob Agents Chemother, 39, pp.2749~2751 (1995)
- Tanimura H, "Gallbladder tissue concentrations, biliary excretion and pharmacokinetics of OPC-17116", Drugs, 49(Suppl 2), pp.341~343 (1995)
- Matsuda S, "Clinical experience with OPC-17116 in the treatment of gynaecological infections and its penetration into gynaecological tissues. Japanese Collaborative Study Group of OPC-17116 in Gynaecology", Drugs, 49(Suppl 2), pp.395~398 (1995)
- Borner K, "A metabolite of sparfloxacin in urine", Drugs, 45(Suppl 3), pp.S303~S304 (1993)
- Radandt JM, "Interactions of fluoroquinolones with other drugs: mechanisms, variability,clinical significance, and management", Clin Infect Dis, 14, pp.272~284 (1992)
- Tanaka M, "Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide", Antimicrob Agents Chemother, 37, pp.2173~2178 (1993)
- Shiba K, "Effects of antacid on absorption and excretion of new quinolones", Drugs, 49(Suppl 2), pp.360~361 (1995)
- Flor S, "Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin", Antimicrob Agents Chemother, 34, pp.2436~2438 (1990)
- Johnson RD, "The effect of sparfioxacin on the pharmacokinetics of theophylline at steady-state conditions", J Clin Pharmacol, 35, pp.936~ (1995)
- Wispelwey B, "Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones", Clin Infect Dis, 41(Suppl 2), pp.S127~S135 (2005)
- Grant EM, "Clinical efficacy and pharmacoeconomics of a continuousinfusion piperacillin-tazobactam program in a large community teaching hospital", Pharmacotherapy, 22, pp.471~483 (2002)
- Dandekar PK, "Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion", Pharmacotherapy, 23, pp.988~991 (2003)
- Ambrose PG, "Clinical pharmacodynamics of quinolones", Infect Dis Clin North Am, 17, pp.529~543 (2003)
- Quintiliani R, "Using pharmacodynamic and pharmacokinetic concepts to optimize treatment of infectious diseases", Infect Med, 21, pp.219~232 (2004)
- Stein GE, "Pharmacokinetics and pharmacodynamics of newer fluoroquinolones", Clin Infect Dis, 23(Suppl 1), pp.S19~S24 (1996)
- MacGowan AP, "Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection", Antimicrob Agents Chemother, 45, pp.2916~2921 (2001)